Cabre P, et al. - An assessment was conducted of the clinical and neuroradiological effectiveness of rituximab (RTX) on active forms of neuromyelitis optica (NMO) at a dose of 375 mg/m²/week for 1 month. A reduction was achieved in the annual relapse rate (ARR) from 1.34 to 0.56 due to rituximab therapy. The inference drawn was that rituximab was clinically effective in active forms of NMO. Nonetheless, few patients were found to be resistant to the treatment.